



03CO  
BOX 56 & 9  
18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GUEGLER et al

Art Unit:

Serial No. 09/731,231

Examiner:

Filed: December 7, 2000

Atty. Docket: CL001007

For: ISOLATED HUMAN KINASE PROTEINS,  
NUCLEIC ACID MOLECULES ENCODING  
HUMAN KINASE PROTEINS, AND USES  
THEREOF

**RESPONSE TO NOTICE OF INCOMPLETE REPLY WITH PETITION FOR 1  
MONTH EXTENSION OF TIME FOR NONPROVISIONAL APPLICATION**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

In response to the "Notice of Incomplete Reply (Nonprovisional Application)"  
mailed May 7, 2001, applicant's Petition is hereby made to extend the current due date so  
as to cover the filing date of this paper. Applicant requests that the extension fee of  
\$110.00 (fee code 115/215) be charged to deposit account number 50-0970. A copy of the  
Notice is submitted herewith.

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.  
The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which  
should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No.  
50-0970**. A duplicate copy of this sheet is attached.

Respectfully submitted,

CELERA GENOMICS

Date: May 24, 2001

By: 

**Justin D. Karjala**

Reg. No. 43,704

Celera Genomics Corporation  
45 West Gude Drive, C2-4#20  
Rockville, MD 20850  
Tel: 240-453-3067  
Fax: 240-453-3084

#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GUEGLER et al

Serial No. 09/731,231

Filed: December 7, 2000



Art Unit:

Examiner:

Atty. Docket: CL001007

For: ISOLATED HUMAN KINASE PROTEINS,  
NUCLEIC ACID MOLECULES ENCODING  
HUMAN KINASE PROTEINS, AND USES  
THEREOF

SUBMISSION OF SEQUENCE LISTING  
UNDER 37 C.F.R. § 1.821(a)

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. § 1.821(a), Applicants submit the Sequence Listing,  
including the paper copy of the Sequence Listing and the computer readable copy of the  
Sequence Listing.

**In the Specification:**

Please enter the Sequence Listing between the specification and the claims of the  
above-identified application.

**REMARKS**

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

It is respectfully believed this application is now in condition for examination.

Early notice to this effect is earnestly solicited.

Respectfully submitted,

CELERA GENOMICS

By:

  
Justin D. Karjala

Reg. No. 43,704

Date: May 24, 2001

Celera Genomics Corporation  
45 West Gude Drive, C2-4#20  
Rockville, MD 20850  
Tel: 240-453-3067  
Fax: 240-453-3084



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/731,231	12/07/2000	Karl Guegler	CL001007

CONFIRMATION NO. 8743

25748  
CELERA GENOMICS CORP.  
ATTN: ROBERT A. MILLMAN, PATENT DIRECTOR  
45 WEST GUDE DRIVE  
C2-4#20  
ROCKVILLE, MD 20850

## FORMALITIES LETTER



\*OC000000006048873\*

Date Mailed: 05/07/2001



## NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

*Filing Date Granted*

The U.S. Patent and Trademark Office has received your reply on to the Notice mailed and it has been entered into the nonprovisional application. The reply, however, does not include the following items required in the Notice.

The period of reply remains as set forth in the Notice. You may, however, obtain EXTENSIONS OF TIME under the provisions of 37 CFR 1.136 (a) accompanied by the appropriate fee (37 CFR 1.17(a)).

A complete reply must be timely filed to prevent ABANDONMENT of the above-identified application.

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

---

*A copy of this notice MUST be returned with the reply.*

A handwritten signature in black ink, appearing to be 'K.B.', is written over a horizontal line.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE